01.06.2026 • Product

Microfluidic Standards: FLTMC Finalist

Microfluidic Standards is one of the finalists for the From Lab to Market Challenge.

Public Voting

Vote now on your favourite start-up in the From Lab to Market Challenge!

Vote Here
Co-Founders
Tobias Fleiss and Lucjan Grzegorzewski, Co-Founders, Microfluidic Standards
© Microfluidic Standards

We spoke with Tobias Fleiss and Lucjan Grzegorzewski (Co-Founders) about Microfluidic Standards, one of the finalists in the From Lab to Market Challenge. 

CHEManager: What is your technology, and what makes it work?

Tobias Fleiss & Lucjan Grzegorzewski: We are building a modular platform for microfluidics to automate handling of tiny amounts of liquids. Design your complex experiment by combining standardized modules like mixers, droplet generators, flowcells, reaction units. Our patented interface enables ultra-small glass chips that are reliable, easy to connect, and up to 40× cheaper. Combined with digital design software, this turns microfluidics into a scalable automation platform.

What problem does your technology solve, and what is the business potential?

T. Fleiss & L. Grzegorzewski: Microfluidics can transform pharma, biotech, chemistry, and diagnostics via lab-on-a-chip systems and miniaturized experiments. Today, systems are costly, and highly custom, often requiring months of engineering and validation per application. Our modular platform reduces development time, integration effort, and material waste, making microfluidics faster, cheaper, and easier to scale, targeting a €40B+ market.

What's the next milestone your team is working towards?

T. Fleiss & L. Grzegorzewski: Our next milestone is validating the first fully modular microfluidic platform with pilot users from academia and industrial R&D. We are expanding our library of standardized chip modules, scaling manufacturing of our interface, and advancing our browser-based design software for simulation and ordering. The goal is to show that complex microfluidic systems can be designed and assembled as fast and easy as electronic circuits.


Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read